Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

March 20, 2018 0

Arena Pharmaceuticals (ARNA) announced positive Phase 2 results from the OASIS trial for etrasimod in ulcerative colitis (UC). The Drug: Etrasimod is a …

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

March 20, 2018 0

What Do We Make of the Following Good News? HERON THERAPEUTICS Will HTX-011 Help in the …

Exelixis: Further Stretching Its Cabozantinib’s Market

March 16, 2018 0

Exelixis (EXEL) completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabometyx® …

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

March 13, 2018 0

Alnylam (ALNY) announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi …

Highlighting Gene Editing Firms

March 12, 2018 0

The Week in Review #19 Targeting the Root-Cause of Diseases - Investing in the Future is …

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

March 8, 2018 0

Extremely important news has come from Montreal, Canada carrying the announcement by Theratechnologies (TSX:TH) and its partner TaiMed …

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

March 6, 2018 0

Regeneron’s (REGN) pipeline products have still a lot of good news to announce. The latest is about …

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

March 5, 2018 0

On March 4, 2018, Aimmune Therapeutics (AIMT) – a biopharmaceutical company developing treatments for potentially life-threatening food allergies …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

February 27, 2018 0

FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system …

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

February 22, 2018 0

The Food and Drug Administration (FDA) approved AstraZeneca (AZN) Checkpoint inhibitor drug Imfinzi® (durvalumab) for patients with unresectable Stage III non-small …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

Exelixis: Further Stretching Its Cabozantinib’s Market

The Prohost Portfolio: Updating the Stock Targets

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

Highlighting Gene Editing Firms

Trogarzo’s FDA Approval Made Possible Managing Multidrug Resistant HIV 1 Infection

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

Thanks to Aimmune, You Might Be Able to Eat Peanut Butter by Next Year

Observing Queer Stories

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

Gilead Collaboration with Sangamo

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

In the Limelight

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit

A Wild Wild Week

Private Lessons and More